EN | RU
EN | RU

Help Support

Back

JNJ-64530440 is well-tolerated in chronic hepatitis B patients

Hepatitis Hepatitis
Hepatitis Hepatitis

What's new?

In patients with chronic hepatitis B, a four-week monotherapy of JNJ-64530440 was well-tolerated and attained significant antiviral activity.

According to the findings of a recent study, oral administration of JNJ-64530440 (a novel hepatitis B virus capsid assembly modulator) for 28 days demonstrated considerable hepatitis B virus (HBV) DNA and RNA reductions and was well-tolerated in treatment-naive people with chronic hepatitis B (CHB). The researchers aimed to investigate the pharmacokinetics, safety and antiviral effect of JNJ-64530440 in CHB.

In this phase 1b trial, 20 treatment-naive, HBeAg-positive or -negative people suffering from CHB were randomly segregated into two groups: (i) JNJ-64530440 group (once-daily/twice-daily): Given 750 mg JNJ-64530440 once or twice everyday, and (ii) Placebo group. All the patients (mean age= 43.8 years) completed dosing/28 days of follow-up.

Mild-to-moderate treatment-associated side effects such as elevated alanine aminotransferase, fatigue, headache, and decreased neutrophil count were observed in 6/8 once-daily group, 4/8 twice-daily group, and 3/4 placebo group. A considerable reduction in HBV DNA was seen, as shown in Table 1.

The levels of HBV DNA observed were under the lower limit of quantification in 5/8 once-daily group and 3/8 twice-daily group. On day 29, the mean (standard error) changes versus baseline in HBV RNA for people with detectable baseline HBV RNA were -2.65 (0.81) log10 copies/mL in the once-daily group and -2.94 (0.33) log10 copies/mL in the twice daily group.

The levels of HBV RNA were noted to be 'target not detected' in 3/7 (twice-daily) group and 4/6 (once-daily) group. JNJ-64530440 pharmacokinetics were similar in CHB patients and healthy volunteers. JNJ-64530440 affects the formation of capsid, reduces the liberation of HBV-RNA-containing particles, and thus appears to be beneficial for the management of people infected with CHB.

Source:

Journal of Antimicrobial Chemotherapy

Article:

Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection

Authors:

Ed J. Gane et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: